People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Or the mysterious relationship between osteoarthritis and obesity. Semaglutide mimics the action of the natural protein glucagon-like peptide 1(GLP-1), a hormone from a family of chemical ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Significant associations for semaglutide initiation included being female, using certain medication classes including antidepressants, and being covered by a point-of-service plan. (HealthDay News ...